Hospital
LA Porte Hospital Company LLC
LA Porte Hospital Company LLC was paid $20.88M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoLA PORTE HOSPITAL COMPANY LLC
LA PORTE, IN 46350
LA PORTE, IN 46350
33aNPI1750746285assigned 12/29/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.88M
24GClaims410,370
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#20 of 69
Median peer was paid$9.76M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,133 | $1.18M | |
| 2019 | 47,708 | $1.73M | |
| 2020 | 43,304 | $1.84M | |
| 2021 | 54,256 | $3.46M | |
| 2022 | 78,953 | $5.00M | |
| 2023 | 75,864 | $4.73M | |
| 2024incomplete | 51,152 | $2.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 29,094 | 23,997 | $4.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 20,274 | 15,511 | $2.93M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 11% | 17,967 | 5,609 | $2.26M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.6% | 1,592 | 1,157 | $1.18M |
| 71045 | Radiologic examination, chest; single view | 4.8% | 7,652 | 5,960 | $1.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 7,819 | 2,469 | $846K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4.0% | 6,635 | 2,035 | $833K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.4% | 482 | 393 | $717K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,512 | 1,084 | $575K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 3,693 | 2,822 | $545K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 830 | 258 | $538K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 7,566 | 5,258 | $469K |
139 more codes
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.5% | 336 | $317K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 1,223 | $313K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.4% | 4,662 | $300K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,091 | $299K |
| 80050 | General health panel | 1.2% | 1,874 | $241K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 2,599 | $226K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,567 | $188K |
| 80053 | Comprehensive metabolic panel | <1% | 34,019 | $178K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,886 | $167K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,542 | $148K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 425 | $133K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,055 | $120K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,400 | $117K |
| 36415 | Collection of venous blood by venipuncture | <1% | 53,656 | $115K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 74 | $113K |
| 62323 | <1% | 151 | $111K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,993 | $105K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,996 | $105K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,222 | $92K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 785 | $86K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 969 | $79K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,842 | $78K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,194 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 817 | $65K |
| 87660 | <1% | 4,229 | $61K | |
| 87480 | <1% | 4,210 | $60K | |
| 87510 | <1% | 4,212 | $60K | |
| 88142 | <1% | 4,153 | $48K | |
| 11043 | <1% | 57 | $40K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,536 | $33K |
| 81001 | <1% | 18,520 | $32K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,118 | $32K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,888 | $31K |
| 43193 | <1% | 22 | $29K | |
| 93017 | <1% | 506 | $27K | |
| 81025 | <1% | 4,522 | $25K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 214 | $24K |
| 84484 | <1% | 3,343 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 117 | $24K |
| 80061 | Lipid panel | <1% | 3,142 | $23K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 179 | $23K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 101 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,705 | $21K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,122 | $19K |
| 87150 | <1% | 587 | $19K | |
| 31231 | <1% | 75 | $19K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 136 | $17K |
| 86803 | <1% | 1,415 | $14K | |
| 83690 | <1% | 3,765 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 67 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 903 | $11K |
| 86850 | <1% | 2,508 | $10K | |
| 83735 | <1% | 3,023 | $10K | |
| 87040 | <1% | 1,829 | $10K | |
| 86762 | <1% | 852 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 354 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 709 | $7K |
| 97162 | <1% | 47 | $6K | |
| 86592 | <1% | 2,014 | $6K | |
| 99221 | <1% | 19 | $6K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 19 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 53 | $6K |
| 87653 | <1% | 252 | $6K | |
| 83605 | <1% | 1,006 | $6K | |
| 85730 | <1% | 2,010 | $5K | |
| 87340 | <1% | 865 | $5K | |
| 86900 | <1% | 2,511 | $5K | |
| 93226 | <1% | 18 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 93 | $5K |
| 83655 | <1% | 428 | $5K | |
| 86901 | <1% | 2,506 | $5K | |
| 97165 | <1% | 47 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 188 | $5K |
| 88342 | <1% | 364 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21 | $5K |
| 83880 | <1% | 329 | $5K | |
| 82728 | <1% | 527 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,021 | $5K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 34 | $5K |
| 80074 | <1% | 109 | $5K | |
| 52000 | <1% | 17 | $4K | |
| 82950 | <1% | 1,081 | $4K | |
| 85660 | <1% | 872 | $4K | |
| 85610 | <1% | 2,034 | $4K | |
| 85027 | <1% | 574 | $4K | |
| 82077 | <1% | 289 | $3K | |
| 93296 | <1% | 51 | $3K | |
| 83550 | <1% | 422 | $3K | |
| 84702 | <1% | 236 | $3K | |
| 88304 | <1% | 312 | $2K | |
| 83540 | <1% | 422 | $2K | |
| 84436 | <1% | 542 | $2K | |
| 87807 | <1% | 107 | $1K | |
| 96367 | <1% | 38 | $1K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 246 | $984.03 |
| 84439 | <1% | 504 | $981.26 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 358 | $898.00 |
| 59025 | Fetal non-stress test | <1% | 68 | $879.57 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $800.44 |
| 85379 | <1% | 45 | $424.47 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 110 | $423.52 |
| 93225 | <1% | 39 | $410.96 | |
| 80076 | <1% | 54 | $407.39 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 135 | $392.34 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $378.27 |
| 82150 | <1% | 161 | $365.64 | |
| 84146 | <1% | 31 | $315.13 | |
| 82247 | <1% | 65 | $311.24 | |
| 81000 | <1% | 187 | $182.22 | |
| 82607 | <1% | 17 | $150.80 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 30 | $147.76 |
| 82550 | <1% | 65 | $144.39 | |
| 80055 | <1% | 15 | $110.55 | |
| 87109 | <1% | 18 | $92.10 | |
| 82553 | <1% | 37 | $73.17 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 917 | $68.66 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,656 | $40.51 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,681 | $6.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,608 | $0.89 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,459 | $0.46 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,619 | $0.00 |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 20 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 90 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 12 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 13 | $0.00 |
| 88313 | 0% | 122 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 86 | $0.00 |
| J3490 | Unclassified drugs | 0% | 38 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 291 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,852 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 378 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 30 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 553 | $0.00 |
| 90744 | 0% | 424 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 33 | $0.00 |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 94 | $0.00 |
| G0010 | Administration of hepatitis b vaccine | 0% | 42 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 15 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.